Gilead Sciences, Inc. (NASDAQ:GILD) Stake Reduced by Weaver C. Barksdale & Associates Inc.

Weaver C. Barksdale & Associates Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 25,209 shares of the biopharmaceutical company’s stock after selling 337 shares during the quarter. Weaver C. Barksdale & Associates Inc.’s holdings in Gilead Sciences were worth $1,730,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CarsonAllaria Wealth Management Ltd. raised its stake in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 238 shares in the last quarter. Palisade Asset Management LLC bought a new stake in shares of Gilead Sciences during the 1st quarter worth about $29,000. Sachetta LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $30,000. Financial Connections Group Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $34,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $36,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ GILD opened at $83.90 on Friday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market capitalization of $104.53 billion, a price-to-earnings ratio of 233.06, a price-to-earnings-growth ratio of 2.80 and a beta of 0.18. The company has a 50 day simple moving average of $76.67 and a 200-day simple moving average of $71.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.40. The company had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. Equities research analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Friday, September 13th. Gilead Sciences’s payout ratio is currently 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock valued at $3,002,940 in the last three months. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Royal Bank of Canada upped their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a research report on Wednesday, September 4th. BMO Capital Markets raised their target price on Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Thursday, June 20th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Raymond James upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price on the stock in a report on Monday, July 8th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $82.06.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.